Supplement Table 1. Antiviral Therapy
Patient Timing Previous Therapy DAA combination Outcome
MELD
DAA start MELD EOT
MELD end of observation
1 pre LT IFN SOF/DCV/RBV SVR 17 13 19
2 pre LT no SOF/LDV/RBV neg EOT 16 15 15
3 pre LT IFN/RBV SOF/DCV SVR 15 13 11
4 pre LT IFN/SOF/RBV SOF/DCV SVR 27 9 8
5 pre LT no SOF/DCV SVR 19 14 14
6 pre LT IFN SOF/SIM SVR 13 13 14
7 pre LT IFN/RBV SOF/LDV SVR 16 16 15
8 pre LT no SOF/LDV/RBV SVR† 21 29 14
9 pre LT SOF/RBV/other DAA SOF/LDV/RBV SVR 16 13 11
10 pre LT IFN/SOF/RBV SOF/LDV SVR 14 16 31
11 pre LT no PTVr/OBV/DSV SVR 21 26 21
12 pre LT no SOF/LDV/RBV SVR 10 12
13 post LT no SOF/VEL SVR 13 11 14
14 pre LT no SOF/LDV/RBV‡ lost to FU
15 pre LT no SOF/LDV/RBV SVR 20 17 13
16 pre LT no SOF/VEL/RBV Relapse 17 16 16
17 pre LT no SOF/VEL/RBV SVR 15 16 17
18 pre LT no SOF/VEL/RBV SVR 16 16 12
19 pre LT no SOF/DCV/RBV death† 23 26 24
20 pre LT IFN/RBV SOF/DCV/RBV SVR 16 12 8
21 pre LT IFN/RBV SOF/LDV/RBV SVR 9 9 6
22 pre LT no SOF/LDV/RBV SVR 12 13 15
23 pre LT IFN/RBV SOF/LDV/RBV SVR 14 15 10
24 pre LT IFN/RBV SOF/DCV/RBV neg EOT 17 18 18
25 pre LT IFN/TVR/RBV SOF/LDV lost to FU 15
26 pre LT IFN/RBV SOF/LDV/RBV SVR 14 17 28
27 pre LT Yes (unknown) SOF/DCV/RBV Relapse 19 19 18
28 pre LT SOF/RBV SOF/LDV/RBV death 24 24 24
29 pre LT IFN/RBV SOF/DCV/RBV SVR 15 15 11
30 pre LT INF/other DAA SOF/LDV/RBV SVR 16 14 14
31 pre LT IFN/RBV SOF/DCV/RBV SVR 17 15 12
Supplement Table 1: Antiviral therapy in patients receiving DAA.
DAA, direct acting antivirals; DCV, Daclatasvir; DSV, Dasabuvir; EOT, end of treatment; FU, follow up; IFN, Interferon; LDV, Ledipasvir; LT, liver transplantation; SVR, sustained virological response; OBV, Ombitasvir; PTVr, Paritaprevir plus Ritonavir;
RBV, Ribavirin; SIM, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; VEL, Velpatasvir
†
cessation due to clinical deterioration
‡
recommended
Supplement Table 2. Clinical parameters with unfavorable outcome after DAA first treatment strategy
Patient
MELD
DAA start Child-Pugh Score outcome comment
3 15 na LT LT due to HCC development 25 months after end of antiviral therapy (SVR) 8 21 11 LT Cessation of antiviral treatment due to kidney function impairment leading
to MELD increase and transplantation
10 14 7 death Death due to acute on chronic liver failure 21 months after end of antiviral therapy (SVR)
19 23 11 death Death due to HCC progress, cessation of antiviral treatment
23 14 na LT LT due to HCC development
26 14 8 death Death due to septic shock including liver failure after orthopedic surgery 7 months after end of antiviral therapy (SVR)
28 24 9 death Death due to acute on chronic liver failure 1 month after start of antiviral treatment 30 16 na death Death due to variceal bleeding 15 months after end of antiviral therapy (SVR)
